AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03442985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene 5.0 mg
Description: Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
Study NCT03442985 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo, once daily, for up to 24 months.
Study NCT03740594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KMC
Description: Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.
Study NCT02980237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth_additional support
Description: An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.
Study NCT02980237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eHealth_program
Description: The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
Study NCT00362453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi versus Attention Control
Description: 60 minutes, twice a week for 12 weeks.
Study NCT00362453 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Tai Chi versus Attention Control
Description: 60 minutes, twice a week for 12 weeks.
Study NCT02800577 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: General Practitioner Emotional Test Battery (GP-ETB)
Description: The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
Study NCT02451241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: electroacupuncture
Study NCT02451241 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: electroacupuncture
Study NCT00534573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride, Moclobemide
Description: Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
Study NCT01688674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10% dextrose
Study NCT01688674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% dextrose
Study NCT01954381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: transthoracic echocardiographic
Study NCT01954381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transthoracic echocardiographic
Study NCT01954381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Doppler ultrasound.
Study NCT01954381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound.
Study NCT01954381 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Study NCT01954381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Study NCT01465204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Sanitation and Sanitation Marketing
Description: Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment.
Study NCT01465204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scaling Up Handwashing Behavior Change
Description: The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
Study NCT03509233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Q-SRP
Description: Quadrant scaling and root planing under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within four sessions in intervals of 1 week
Study NCT03509233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMS
Description: Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours
Study NCT03509233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMD
Description: Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours with additional disinfection using 0.2% chlorhexidine (mouth rinsing and tonsil spray), subgingival application of 1% chlorhexidine gel and 2 months postoperative home care using chlorhexidine 0.2% (rinse and spray)
Study NCT03509233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMDP
Description: FMD protocol (see FMD arm) with additional use of subgingival airpolishing (Air Flow, EMS) using Erythritol powder (Air-Flow Plus powder, EMS) for 20 seconds per tooth
Study NCT01386060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
Study NCT04123834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patella tendon & bone block autograft + press-fit femoral technique
Description: Implantless Arthroscopic ACL reconstruction using press-fit femoral technique The investigator's study uses the press-fit graft fixation technique by Edgar Michael. A midline skin incision was made that extends from inferior pole of patella up to anterior tibial tuberosity. Patella tendon with tibial tuberosity bone block were harvested, patella bone was left intact. The tendon was fixed together with non-absorbable suture.
Study NCT04123834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL reconstruction
Description: Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)
Study NCT04123834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft + implant fixation
Description: Arthroscopic ACL reconstruction with implant (using hamstring tendon autograft fixed with bioscrew and endo-button)
Study NCT02342743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFALY
Study NCT04124081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone capsules& Entecavir capsules
Description: take the Hydronidone capsule and then the entecavir capsule, and then take the last two together
Study NCT00629434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes education via telemedicine
Description: This arm will receive diabetes group education via telemedicine
Study NCT00629434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diabetes education in-person
Description: In this arm the group of patients with diabetes will receive diabetes education in-person
Study NCT00701233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: 45 units Botox injected into Carpal Tunnel once
Study NCT00701233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection into Carpal Tunnel
Description: 40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
Study NCT03602066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorine Dioxide Sterilization
Description: Given via oral rinse
Study NCT03602066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03602066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03602066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given via oral rinse
Study NCT04266665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
Study NCT04266665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
Study NCT00092495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Description: qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
Study NCT04931186 — intervention group
Intervention type: OTHER
Intervention: retrospective analyis
Description: retrospective analysis of data
Study NCT00782522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric training program
Description: Eccentric training program
Study NCT00782522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training program
Description: Traditional training program
Study NCT02859532 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: elastography SWIRE
Study NCT03182725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
Study NCT03182725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that has no therapeutic effect and will act as a control.
Study NCT02179723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leukosan Adhesive
Description: Leukosan adhesive applied to one wound
Study NCT02179723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leukosan Adhesive
Description: Leukosan adhesive applied to one wound
Study NCT02179723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous suture
Description: Transcutaneous suture applied to one wound
Study NCT02179723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous suture
Description: Transcutaneous suture applied to one wound
Study NCT02430974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients in experimental group will receive oral Icotinib for 4-8months.
Study NCT02768051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF Ablation
Study NCT00674869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pit and fissure sealant
Description: pit and fissure sealant on one randomized tooth by pair of permanent molar
Study NCT04637308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylated gelatin
Description: Succinylated gelatin (SG, Gelofusine; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular weight (MWw) 30 kDa.
Study NCT01648738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy, exercise and educational therapy
Description: During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
Study NCT01648738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
Study NCT04559880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injection [Cyklokapron]
Description: Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
Study NCT01535014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietressa
Description: Comparison of different dosages (frequency) of drug
Study NCT01535014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)
Study NCT01143038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim will be administered weekly by subcutaneous injection
Study NCT01108250 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: LOC387715/HTRA1 genotyping
Description: Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
Study NCT01108250 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LOC387715/HTRA1 genotyping
Description: Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
Study NCT02489513 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [14C]-AG-120
Description: Labeled investigational drug
Study NCT00862355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC147609
Description: IV infusion
Study NCT00862355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference147609
Description: IV infusion
Study NCT03310268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total
Description: Participants will be instructed to apply experimental dentifrice (containing 454% SnF2 and 0.072% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
Study NCT03310268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1400 ppm fluoride as sodium monofluorophosphate (SMFP)
Description: Participants will be instructed to apply negative control dentifrice (containing 1400 ppm fluoride as SMFP), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
Study NCT03310268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total
Description: Participants will be instructed to apply positive control dentifrice (containing SnCl2 and 0.15% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
Study NCT04265924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fraction of inspired oxygen (FIO2)
Description: The fraction of inspired oxygen (FIO2) is given accordingly (>0.85 for the >0.85 group, and \<0.7 for the \<0.7 group) to the patients during the surgery.
Study NCT02998736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cialis
Description: Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery
Study NCT02998736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: One 0.5mL intramuscular injection the day of surgery
Study NCT04519112 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter Ablation with RMN and MCN
Study NCT04519112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Catheter Ablation with RMN and MCN
Study NCT00956514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
Study NCT04490733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dual-task walking
Description: Participants will receive 3 times interventions during 10th to 12th course of chemotherapy and 12 weekly phone-call to assess effect and barriers of dual-task walking.
Study NCT01939054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Study NCT01939054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT01939054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Study NCT01939054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT01939054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT02397811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteric Coated Softgels
Description: Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
Study NCT02397811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal astaxanthin
Description: Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
Study NCT02397811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Softgel
Description: Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
Study NCT02397811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin Water Soluble Emulsion
Description: Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
Study NCT02397811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin Water Dispersible Powder
Description: Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
Study NCT02397811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Softgel with Astaxanthin Gel
Description: Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
Study NCT02065141 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sip feeding with stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
Study NCT04295980 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical removal of the BAVMs
Description: Resection the BAVM nidus by microsurgery.
Study NCT01637623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
Study NCT01637623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300 mg daily for 6 weeks
Study NCT01637623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule daily for 6 weeks
Study NCT01539304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CITUS Dry Syrup
Description: Pranlukast 10% dry syrup, b.i.d.
Study NCT01539304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dry syrup, b.i.d
Study NCT02930356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NSPT
Description: NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
Study NCT02930356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.